HUE038501T2 - Antitest készítmények - Google Patents

Antitest készítmények

Info

Publication number
HUE038501T2
HUE038501T2 HUE15155712A HUE15155712A HUE038501T2 HU E038501 T2 HUE038501 T2 HU E038501T2 HU E15155712 A HUE15155712 A HU E15155712A HU E15155712 A HUE15155712 A HU E15155712A HU E038501 T2 HUE038501 T2 HU E038501T2
Authority
HU
Hungary
Prior art keywords
antibody formulations
antibody
formulations
Prior art date
Application number
HUE15155712A
Other languages
English (en)
Inventor
Charlene E Brisbane
Amol Sharad Ketkar
Ulla Tove Lashmar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228991&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE038501(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE038501T2 publication Critical patent/HUE038501T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
HUE15155712A 2007-07-06 2008-07-03 Antitest készítmények HUE038501T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94822007P 2007-07-06 2007-07-06

Publications (1)

Publication Number Publication Date
HUE038501T2 true HUE038501T2 (hu) 2018-10-29

Family

ID=40228991

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE08781323A HUE031288T2 (hu) 2007-07-06 2008-07-03 Anti-CD20 antitest készítmények
HUE15155712A HUE038501T2 (hu) 2007-07-06 2008-07-03 Antitest készítmények
HUS2100038C HUS2100038I1 (hu) 2007-07-06 2021-09-15 Anti-CD20 antitest készítmények

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE08781323A HUE031288T2 (hu) 2007-07-06 2008-07-03 Anti-CD20 antitest készítmények

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2100038C HUS2100038I1 (hu) 2007-07-06 2021-09-15 Anti-CD20 antitest készítmények

Country Status (38)

Country Link
US (2) US20110020328A1 (hu)
EP (2) EP2889310B1 (hu)
JP (1) JP5529017B2 (hu)
KR (2) KR101670454B1 (hu)
CN (1) CN101820912B (hu)
AR (2) AR067455A1 (hu)
AU (1) AU2008275278B2 (hu)
BR (2) BRPI0814003B1 (hu)
CA (1) CA2692681C (hu)
CL (1) CL2008001984A1 (hu)
CO (1) CO6270340A2 (hu)
CR (1) CR11249A (hu)
CY (2) CY1118419T1 (hu)
DK (2) DK2170388T3 (hu)
DO (1) DOP2010000001A (hu)
EA (1) EA017994B1 (hu)
ES (2) ES2610821T3 (hu)
FR (1) FR21C1040I1 (hu)
HK (2) HK1141979A1 (hu)
HR (2) HRP20170033T1 (hu)
HU (3) HUE031288T2 (hu)
IL (1) IL202950A (hu)
JO (1) JO3219B1 (hu)
LT (3) LT2889310T (hu)
MA (1) MA31471B1 (hu)
MX (1) MX2010000017A (hu)
NO (2) NO2889310T3 (hu)
NZ (1) NZ582250A (hu)
PE (1) PE20090738A1 (hu)
PL (2) PL2170388T3 (hu)
PT (2) PT2889310T (hu)
SI (2) SI2889310T1 (hu)
TR (1) TR201802928T4 (hu)
TW (2) TWI612060B (hu)
UA (1) UA107557C2 (hu)
UY (1) UY31210A1 (hu)
WO (1) WO2009009407A1 (hu)
ZA (1) ZA200909107B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP2010532790A (ja) * 2007-07-06 2010-10-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
BR112012030139A2 (pt) 2010-05-28 2017-06-13 Novo Nordisk As composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante
EP2694708A4 (en) * 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS WITH REDUCED VISCOSITY
WO2012151247A2 (en) * 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN111973484A (zh) * 2013-03-12 2020-11-24 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
EP2805730A1 (en) * 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
WO2017136433A1 (en) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
CA3030530C (en) 2016-08-15 2021-02-23 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
WO2018179138A1 (ja) * 2017-03-29 2018-10-04 持田製薬株式会社 抗体含有液体製剤
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
US11513046B2 (en) * 2018-02-09 2022-11-29 Championx Usa Inc. Flowability testing systems and methods
WO2021048279A1 (en) 2019-09-11 2021-03-18 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
SI3864053T1 (sl) 2019-09-11 2023-12-29 Novartis Ag Zdravljenje rms-ja z menjavo terapije
CN112675126A (zh) * 2019-10-18 2021-04-20 百奥泰生物制药股份有限公司 抗cd20抗体制剂及其应用
AU2021253674A1 (en) 2020-04-09 2022-11-03 Novartis Ag Ofatumumab for treating MS while maintaining serum IgG
JP7057954B2 (ja) * 2020-09-03 2022-04-21 国立大学法人大阪大学 改善された保存安定性を有するタンパク質含有液体製剤
KR20230170923A (ko) 2021-04-14 2023-12-19 노파르티스 아게 아시아인 환자들에서 ms 치료용 오파투무맙
WO2023020802A1 (en) 2021-08-16 2023-02-23 Novartis Ag Ofatumumab for treating pediatric ms
WO2023204554A1 (ko) * 2022-04-20 2023-10-26 주식회사 알토스바이오로직스 오크렐리주맙을 포함하는 약학적 조성물과 그의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
AU740284B2 (en) * 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
BR0014486A (pt) * 1999-10-04 2002-09-17 Chiron Corp Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN101914158A (zh) 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
JP4583762B2 (ja) * 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
NZ537687A (en) * 2002-06-21 2008-04-30 Biogen Idec Inc Buffered formulations for concentrating antibodies and methods of use thereof
PT3284753T (pt) * 2002-10-17 2020-05-04 Genmab As Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla
JP4739763B2 (ja) * 2002-12-16 2011-08-03 ゲンマブ エー/エス インターロイキン8(il−8)に対するヒトモノクローナル抗体
US8084582B2 (en) * 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー/エスGenmab A/S Cd20に対するヒトモノクローナル抗体
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
CA2600608A1 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
SI1942939T2 (sl) * 2005-09-30 2021-11-30 Medimmune Limited Sestavek protitelesa proti interlevkinu-13
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
JP2010532790A (ja) * 2007-07-06 2010-10-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方

Also Published As

Publication number Publication date
KR20150088335A (ko) 2015-07-31
KR101670454B1 (ko) 2016-10-31
UY31210A1 (es) 2009-01-30
IL202950A0 (en) 2011-08-01
WO2009009407A1 (en) 2009-01-15
EA201070105A1 (ru) 2010-08-30
IL202950A (en) 2014-05-28
BRPI0814003B1 (pt) 2021-06-15
EP2889310A1 (en) 2015-07-01
BRPI0814003A2 (pt) 2015-02-03
CY1120047T1 (el) 2018-12-12
CR11249A (es) 2010-03-08
US20150158951A1 (en) 2015-06-11
HUE031288T2 (hu) 2017-06-28
NO2021036I1 (no) 2021-09-13
ES2610821T3 (es) 2017-05-03
HK1141979A1 (zh) 2010-11-26
CA2692681C (en) 2018-12-04
PE20090738A1 (es) 2009-07-18
SI2170388T1 (sl) 2017-01-31
TW201623334A (zh) 2016-07-01
CN101820912A (zh) 2010-09-01
CL2008001984A1 (es) 2009-01-09
NO2889310T3 (hu) 2018-05-19
LT2170388T (lt) 2017-01-10
SI2889310T1 (en) 2018-04-30
PL2889310T3 (pl) 2018-06-29
MA31471B1 (fr) 2010-06-01
DK2170388T3 (en) 2017-01-16
LTPA2021520I1 (hu) 2021-10-11
JP2011526880A (ja) 2011-10-20
HRP20170033T1 (hr) 2017-03-24
TR201802928T4 (tr) 2018-03-21
AU2008275278B2 (en) 2011-04-14
HUS2100038I1 (hu) 2021-10-28
CN101820912B (zh) 2014-03-12
LT2889310T (lt) 2018-03-26
AU2008275278A1 (en) 2009-01-15
EP2170388B1 (en) 2016-10-12
PT2889310T (pt) 2018-03-26
DK2889310T3 (en) 2018-03-26
JO3219B1 (ar) 2018-03-08
MX2010000017A (es) 2010-04-07
US20110020328A1 (en) 2011-01-27
AR067455A1 (es) 2009-10-14
CY1118419T1 (el) 2017-06-28
ES2663504T3 (es) 2018-04-13
AR109461A2 (es) 2018-12-12
TWI612060B (zh) 2018-01-21
JP5529017B2 (ja) 2014-06-25
UA107557C2 (xx) 2015-01-26
DOP2010000001A (es) 2010-01-31
ZA200909107B (en) 2012-12-27
TW200914466A (en) 2009-04-01
EP2170388A4 (en) 2011-07-06
PL2170388T3 (pl) 2017-06-30
KR20100038092A (ko) 2010-04-12
NZ582250A (en) 2012-04-27
TWI515204B (zh) 2016-01-01
PT2170388T (pt) 2017-01-04
EP2889310B1 (en) 2017-12-20
FR21C1040I1 (fr) 2021-11-19
HK1207652A1 (en) 2016-02-19
BR122020026978B1 (pt) 2021-09-28
CO6270340A2 (es) 2011-04-20
HRP20180440T1 (hr) 2018-04-20
EA017994B1 (ru) 2013-04-30
CA2692681A1 (en) 2009-01-15
EP2170388A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
HRP20182146T1 (hr) Formulacije protutijela natalizumab
HK1214947A1 (zh) 抗體製劑
EP2173163A4 (en) ANTIBODY FORMULATIONS
IL200321A0 (en) Stable antibody formulations
EP2077859A4 (en) ANTIBODY FORMULATION
SG10201604258YA (en) Anti-tnf antibody formulations
HK1136970A1 (en) Penta-specific antibody
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
IL205073A0 (en) Anti-bst2 antibody
GB0710899D0 (en) Formulations
EP2167635A4 (en) ANTIBODY FORMULATIONS
GB0705179D0 (en) Formulations
GB0723900D0 (en) Lyophillised antigen composition
GB0723044D0 (en) Lyophillised antigen composition
GB0701993D0 (en) Formulations
GB0708663D0 (en) Formulations
GB0710346D0 (en) Formulations
GB0710350D0 (en) Formulations